Grace Therapeutics Inc.

NASDAQ: GRCE · Real-Time Price · USD
3.08
-0.20 (-6.10%)
At close: Aug 14, 2025, 3:59 PM
2.90
-5.69%
After-hours: Aug 14, 2025, 05:45 PM EDT

Grace Therapeutics Income Statement

Financials in USD. Fiscal year is April - March.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022
Revenue
n/a n/a n/a n/a
Cost of Revenue
7K 11K 124K n/a
Gross Profit
-7K -11K -124K n/a
Operating Income
-16.68M -12.85M -52.16M -15.59M
Interest Income
711K 911K 246K 77K
Pretax Income
-12.77M -14.69M -51.97M -10.47M
Net Income
-12.77M -12.85M -42.43M -9.82M
Selling & General & Admin
7.17M 6.64M 8.21M 9.78M
Research & Development
9.51M 4.68M 9.97M 5.56M
Other Expenses
n/a 1.52M 33.97M 249K
Operating Expenses
16.68M 12.85M 52.16M 15.59M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a 194K 136K 116K
Cost & Expenses
16.68M 12.85M 52.16M 15.59M
Income Tax Expense
-3.2M -1.83M -9.54M -648K
Shares Outstanding (Basic)
12.09M 7.44M 7.43M 6.14M
Shares Outstanding (Diluted)
12.09M 7.44M 7.43M 6.14M
EPS (Basic)
-0.79 -1.73 -5.71 -1.6
EPS (Diluted)
-0.79 -1.73 -5.71 -1.6
EBITDA
-12.76M -11.33M -18.12M -15.34M
EBIT
-12.77M -11.37M -18.25M -15.34M
Depreciation & Amortization
7K 11K 124K n/a